Marion Subklewe – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 08 Mar 2023 10:35:17 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Marion Subklewe – VJRegenMed https://mirror.vjregenmed.com 32 32 The importance of managing hematologic toxicity associated with CAR-T therapy https://mirror.vjregenmed.com/video/2riqxiyofqs-the-importance-of-managing-hematologic-toxicity-associated-with-car-t-therapy/ Wed, 08 Mar 2023 10:35:17 +0000 https://mirror.vjregenmed.com/video/2riqxiyofqs-the-importance-of-managing-hematologic-toxicity-associated-with-car-t-therapy/ In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, comments on the importance of improving methods of assessing and managing hematologic toxicity associated with the use of CAR-T therapy. Prof. Subklewe also shares some insights into the novel CAR-HEMATOTOX risk stratification tool being evaluated in patients treated with CAR-T therapy for various hematological malignancies. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]> CAR-T vs. BiTEs in B-cell malignancies https://mirror.vjregenmed.com/video/1iedhmsgcn4-car-t-vs-bites-in-b-cell-malignancies/ Fri, 26 Feb 2021 14:08:22 +0000 http://13.40.107.223/video/1iedhmsgcn4-car-t-vs-bites-in-b-cell-malignancies/ Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, compares CAR T-cells to bispecific T-cell engagers (BiTEs). Firstly, Prof. Subklewe highlights that there are no randomized trials in any disease comparing CAR T-cells to BiTEs. Different parameters can be compared between CAR T-cells and BiTEs, including construct design, manufacturing, and production time. Additionally, data from clinical trials can provide insights into aspects such as safety and efficacy. Compared to CAR-T therapies, the BiTE platform provides an off-the-shelf product with a high safety profile, which are significant advantages. In the future, predictive biomarkers are needed to stratify patients to the safest and most successful treatment option. This interview took place during the 3rd European CAR T-cell Meeting.

]]> CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias https://mirror.vjregenmed.com/video/3nztx3tttzq-car-t-cell-toxicity-crs-icans-and-prolonged-cytopenias/ Fri, 26 Feb 2021 14:08:22 +0000 http://13.40.107.223/video/3nztx3tttzq-car-t-cell-toxicity-crs-icans-and-prolonged-cytopenias/ Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses recognition and treatment of CAR T-cell therapy-related side effects, including novel insights into the pathophysiology of long-term cytopenias. Close monitoring and timely intervention with tocilizumab with or without corticosteroids remain the best management strategies for cytokine release syndrome (CRS). The pathogenesis of neurotoxicity is not fully understood and it remains very challenging to manage. Similar to CRS management, neurotoxicity needs to be promptly recognized. Additionally, Prof. Subklewe shares the latest updates regarding prolonged cytopenias. This interview took place during the 3rd European CAR T-cell Meeting.

]]>